JP2022547358A - 治療組成物、組み合わせ、及び使用方法 - Google Patents

治療組成物、組み合わせ、及び使用方法 Download PDF

Info

Publication number
JP2022547358A
JP2022547358A JP2020547414A JP2020547414A JP2022547358A JP 2022547358 A JP2022547358 A JP 2022547358A JP 2020547414 A JP2020547414 A JP 2020547414A JP 2020547414 A JP2020547414 A JP 2020547414A JP 2022547358 A JP2022547358 A JP 2022547358A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cancer
acceptable salt
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020547414A
Other languages
English (en)
Japanese (ja)
Inventor
ウダイ バナルジ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to JP2020153323A priority Critical patent/JP7634351B2/ja
Publication of JP2022547358A publication Critical patent/JP2022547358A/ja
Priority to JP2025020124A priority patent/JP2025072587A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020547414A 2019-09-13 2019-09-13 治療組成物、組み合わせ、及び使用方法 Pending JP2022547358A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020153323A JP7634351B2 (ja) 2019-09-13 2020-09-11 治療組成物、組み合わせ、及び使用方法
JP2025020124A JP2025072587A (ja) 2019-09-13 2025-02-10 治療組成物、組み合わせ、及び使用方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer

Publications (1)

Publication Number Publication Date
JP2022547358A true JP2022547358A (ja) 2022-11-14

Family

ID=67988988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020547414A Pending JP2022547358A (ja) 2019-09-13 2019-09-13 治療組成物、組み合わせ、及び使用方法
JP2020153323A Active JP7634351B2 (ja) 2019-09-13 2020-09-11 治療組成物、組み合わせ、及び使用方法
JP2025020124A Pending JP2025072587A (ja) 2019-09-13 2025-02-10 治療組成物、組み合わせ、及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020153323A Active JP7634351B2 (ja) 2019-09-13 2020-09-11 治療組成物、組み合わせ、及び使用方法
JP2025020124A Pending JP2025072587A (ja) 2019-09-13 2025-02-10 治療組成物、組み合わせ、及び使用方法

Country Status (11)

Country Link
US (4) US11517573B2 (https=)
EP (1) EP4028010B1 (https=)
JP (3) JP2022547358A (https=)
KR (1) KR102945599B1 (https=)
CN (2) CN114630667B (https=)
AU (1) AU2020344829A1 (https=)
BR (1) BR112022004699A2 (https=)
CA (1) CA3152805A1 (https=)
MX (1) MX2022003063A (https=)
TW (1) TWI857024B (https=)
WO (3) WO2021047783A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
MX2022009612A (es) 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.
AU2021307410A1 (en) * 2020-07-13 2023-02-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4376828A4 (en) * 2021-07-27 2025-06-18 Verastem, Inc. COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
IL312248A (en) * 2021-10-28 2024-06-01 Verastem Inc Combined treatment for abnormal cell proliferation
IL312469A (en) * 2021-11-02 2024-06-01 Verastem Inc Methods of treating abnormal cell growth
TW202329967A (zh) * 2022-01-21 2023-08-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
KR101489045B1 (ko) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013170066A1 (en) 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for the treatment of cancer
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR20150067323A (ko) 2012-10-12 2015-06-17 글락소스미스클라인 엘엘씨 조합물
SG10201805890QA (en) 2014-01-09 2018-08-30 Verastem Inc Compositions and methods for treatment of abnormal cell growth
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
RU2760006C1 (ru) 2017-11-16 2021-11-22 Дзе Инститьют оф Кансер Рисерч: Ройал Кансер Хоспитал Производное кумарина для лечения или профилактики расстройства пролиферации клеток
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Also Published As

Publication number Publication date
US11517573B2 (en) 2022-12-06
CA3152805A1 (en) 2021-03-18
JP2025072587A (ja) 2025-05-09
US20220031698A1 (en) 2022-02-03
TW202114677A (zh) 2021-04-16
JP2022172480A (ja) 2022-11-17
BR112022004699A2 (pt) 2022-06-14
TWI857024B (zh) 2024-10-01
CN114630667A (zh) 2022-06-14
AU2020344829A1 (en) 2022-03-03
KR102945599B1 (ko) 2026-03-30
JP7634351B2 (ja) 2025-02-21
MX2022003063A (es) 2022-06-14
US20240197731A1 (en) 2024-06-20
WO2021047798A1 (en) 2021-03-18
WO2021048339A1 (en) 2021-03-18
KR20220078606A (ko) 2022-06-10
US12280050B2 (en) 2025-04-22
EP4028010A1 (en) 2022-07-20
WO2021047783A1 (en) 2021-03-18
EP4028010B1 (en) 2026-04-08
US20230277535A1 (en) 2023-09-07
CN114630667B (zh) 2025-05-13
US20260034128A1 (en) 2026-02-05
CN120678780A (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
JP7634351B2 (ja) 治療組成物、組み合わせ、及び使用方法
JP2022172480A5 (https=)
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
JP7578643B2 (ja) 異常な細胞成長を処置するための方法および組成物
US20230103007A1 (en) Combination therapy for treating abnormal cell growth
JP2024528039A (ja) 異常な細胞成長を処置するための組み合わせ治療
KR20260046532A (ko) 암 치료를 위한 ch5126766과 조합된 vs-6063
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20200910

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20200910